Over the past decade, advances in genomics, proteomics platforms, and biomarker detection techniques have led to the identification of many new biomarkers to improve the diagnosis of HCC, such as osteopontin (OPN), microRNAs, and MDK [27]. This evidence concerns the gene MDK and hepatocellular carcinoma.